Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Vanda Pharmaceuticals Inc is a biotechnology business based in the US. Vanda Pharmaceuticals shares (VNDA) are listed on the NASDAQ and all prices are listed in US Dollars. Vanda Pharmaceuticals employs 292 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$18.15|
|52-week range||$10.07 - $21.86|
|50-day moving average||$17.38|
|200-day moving average||$17.78|
|Wall St. target price||$24.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.57|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||1.91%|
|1 month (2021-09-27)||3.24%|
|3 months (2021-07-27)||-5.96%|
|6 months (2021-04-27)||7.65%|
|1 year (2020-10-26)||74.02%|
|2 years (2019-10-25)||29.27%|
|3 years (2018-10-26)||20.51|
|5 years (2016-10-26)||19.80%|
Valuing Vanda Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vanda Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vanda Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Vanda Pharmaceuticals shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Vanda Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.8 million.
The EBITDA is a measure of a Vanda Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$258.5 million|
|Operating margin TTM||15.82%|
|Gross profit TTM||$224.8 million|
|Return on assets TTM||4.76%|
|Return on equity TTM||7.11%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
There are currently 4.7 million Vanda Pharmaceuticals shares held short by investors – that's known as Vanda Pharmaceuticals's "short interest". This figure is 0.5% down from 4.7 million last month.
There are a few different ways that this level of interest in shorting Vanda Pharmaceuticals shares can be evaluated.
Vanda Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Vanda Pharmaceuticals shares currently shorted divided by the average quantity of Vanda Pharmaceuticals shares traded daily (recently around 320277.88331072). Vanda Pharmaceuticals's SIR currently stands at 14.74. In other words for every 100,000 Vanda Pharmaceuticals shares traded daily on the market, roughly 14740 shares are currently held short.
However Vanda Pharmaceuticals's short interest can also be evaluated against the total number of Vanda Pharmaceuticals shares, or, against the total number of tradable Vanda Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vanda Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Vanda Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.106% of the tradable shares (for every 100,000 tradable Vanda Pharmaceuticals shares, roughly 106 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vanda Pharmaceuticals.
Find out more about how you can short Vanda Pharmaceuticals stock.
We're not expecting Vanda Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Vanda Pharmaceuticals's shares have ranged in value from as little as $10.07 up to $21.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vanda Pharmaceuticals's is 0.5026. This would suggest that Vanda Pharmaceuticals's shares are less volatile than average (for this exchange).
Vanda Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.